Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced/ Metastatic Her-2 Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Large-scale testing (Phase 3)Looking for participantsNCT07413939
What this trial is testing

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Who this might be right for
HER2-positive Breast Cancer
Hoffmann-La Roche 650
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02675231
What this trial is testing

Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CancerHER-2 Positive Breast Cancer
Eli Lilly and Company 237
Not applicableStudy completedNCT03025711
What this trial is testing

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

Who this might be right for
Breast Neoplasms
BELEN RUIZ-ANTORAN 220
Large-scale testing (Phase 3)Active Not RecruitingNCT02107703
What this trial is testing

Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 669
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Large-scale testing (Phase 3)Looking for participantsNCT07008976
What this trial is testing

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 246
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)Ended earlyNCT00657137
What this trial is testing

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Who this might be right for
Breast Cancer
Tragara Pharmaceuticals, Inc. 12
Testing effectiveness (Phase 2)UnknownNCT03997539
What this trial is testing

Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-sen University 256
Testing effectiveness (Phase 2)Study completedNCT01044485
What this trial is testing

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Centre Georges Francois Leclerc 17
Large-scale testing (Phase 3)Study completedNCT01120184
What this trial is testing

Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,095
Testing effectiveness (Phase 2)WithdrawnNCT05227131
What this trial is testing

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerHER2-positive Breast Cancer
MedSIR
Early research (Phase 1)Active Not RecruitingNCT04042701
What this trial is testing

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Who this might be right for
Breast CancerNon-small Cell Lung Carcinoma
Daiichi Sankyo 115
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Next Page